Core Points - Two companies, Huiyuan Communication and Hualan Group, are undergoing changes in control and will resume trading on November 19, 2025 [2][3] - Aik Shares is planning to issue shares to acquire assets and will be suspended from trading starting November 19, 2025 [5] - ST Zhengping's stock has seen a significant increase of 221.93% from September 1 to November 18, 2025, leading to a suspension for verification [6] - Tianyima plans to acquire 98.5632% of Xingyun Kaiwu for 1.1885 billion yuan and will issue shares to raise up to 155 million yuan [9] Group 1: Control Changes - Huiyuan Communication plans to issue up to 53.65 million shares at 11.37 yuan per share, raising a total of up to 610 million yuan, with the proceeds used for working capital [2] - Hualan Group's actual controllers will transfer a total of 851.13 million shares (5.79% of total shares) to Xutong Investment at a price of 20.41 yuan per share, totaling 174 million yuan [3] Group 2: Suspensions and Resumptions - Aik Shares will be suspended from trading as it plans to issue shares and cash to acquire Dongguan Silicon Xiang Insulation Materials Co., Ltd. [5] - ST Zhengping's stock will be suspended for verification due to its stock price significantly deviating from fundamentals [6] - ST Dongyi has completed its verification work and will resume trading on November 19, 2025 [11] Group 3: Major Asset Restructuring - Tianyima is planning a major asset restructuring by acquiring a majority stake in Xingyun Kaiwu for 1.1885 billion yuan [9] - Meng Tian Home has terminated its asset restructuring and control change plans, leading to its resumption of trading [9] Group 4: Fundraising Activities - Jin An Guo Ji plans to raise up to 1.29995 billion yuan through a private placement for a high-grade copper-clad laminate project [9] - Wan Tong Technology is also planning a private placement to raise up to 920 million yuan for working capital [9]

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-088 宁波三星医疗电气股份有限公司 关于经营合同预中标的提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）及下属全资子公司宁波奥克 斯智能科技股份有限公司（以下简称"奥克斯智能科技"）于近日在国网江苏省电力有 限公司 2025 年第二次配网物资协议库存公开招标采购项目、国网安徽电力 2025 年第 二次物资协议库存公开招标采购项目中被推荐为中标候选人，预计合计中标总金额约 为 12,529.07 万元，现将预中标情况公告如下： 一、国家电网项目预中标的主要内容 1、国网江苏省电力有限公司2025年第二次配网物资协议库存公开招标采购项目 国家电网有限公司于近日在其电子商务平台（http://ecp.sgcc.com.cn）公告"国网 江苏省电力有限公司2025年第二次配网物资协议库存公开招标采购推荐的中标候选 人公示"（招标编号：1025AB），奥克斯智能科技为中标候选人。 https://ecp.sgcc. ...

Group 1 - Samsung Medical (601567.SH) announced that it and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd. (referred to as "Aux Intelligent Technology"), have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd. for the year 2025 [1] - The total expected bid amount for these projects is approximately 125 million yuan [1]

Core Insights - Samsung Medical (601567.SH) announced that it and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd. for 2025 [1] Group 1 - The total expected bid amount for the projects is approximately 125 million yuan [1]

Core Viewpoint - Samsung Medical (601567.SH) and its wholly-owned subsidiary, Ningbo Aux Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd., with a total expected bid amount of approximately 125 million yuan [1] Group 1 - The company has participated in the 2025 second round of public procurement projects for inventory materials [1] - The total expected bid amount from both projects is around 125 million yuan [1]

Core Viewpoint - Samsung Medical announced that it and its wholly-owned subsidiary, Aix Smart Technology, have been recommended as candidates for winning bids in two public procurement projects by State Grid Jiangsu Electric Power Company and State Grid Anhui Electric Power Company, with a total expected bid amount of approximately 125.29 million yuan [1] Group 1 - The total expected bid amount for the projects is approximately 125.29 million yuan [1] - The project with State Grid Jiangsu Electric Power Company is expected to win a bid of 64.71 million yuan [1] - The project with State Grid Anhui Electric Power Company is expected to win a bid of 60.58 million yuan [1] Group 2 - Winning these bids is anticipated to have a positive impact on the company's performance [1] - The company has not yet received the official bid notification, indicating uncertainty regarding the performance impact [1]

Core Viewpoint - Samsung Medical (601567) announced that it and its wholly-owned subsidiary, Ningbo Aokeshi Intelligent Technology Co., Ltd., have been recommended as candidates for winning bids in two public procurement projects for inventory materials by State Grid Jiangsu Electric Power Co., Ltd. and State Grid Anhui Electric Power Co., Ltd., with a total expected bid amount of approximately 125 million yuan [1]. Group 1 - Company and its subsidiary have been recommended as winning candidates in public procurement projects [1] - Total expected bid amount is approximately 125 million yuan [1]

Group 1 - On November 17, Samsung Medical experienced a decline of 2.46% with a trading volume of 472 million yuan, and the net financing buy was -41.71 million yuan [1] - As of November 17, the total financing and securities lending balance for Samsung Medical was 308 million yuan, with a financing balance of 304 million yuan, accounting for 0.84% of the circulating market value [1] - The company’s main business revenue composition includes 79.70% from the power sector, 19.15% from medical services, and 1.15% from other businesses [1] Group 2 - As of September 30, the number of shareholders for Samsung Medical increased by 15.72% to 33,500, while the average circulating shares per person decreased by 13.94% to 41,941 shares [2] - For the period from January to September 2025, Samsung Medical reported a revenue of 11.08 billion yuan, representing a year-on-year growth of 6.19%, while the net profit attributable to the parent company was 1.528 billion yuan, a decrease of 15.85% year-on-year [2] Group 3 - Since its A-share listing, Samsung Medical has distributed a total of 6.407 billion yuan in dividends, with 3.329 billion yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 51.056 million shares, an increase of 3.0756 million shares compared to the previous period [3]

Core Viewpoint - Samsung Medical has been recognized as a candidate for a major procurement project by the State Grid Corporation of China, with an expected total bid amount of approximately 168 million yuan, which will strengthen its position in the domestic power grid market and drive annual performance growth [1][2]. Group 1: Recent Achievements - Samsung Medical's subsidiary, Aixs Intelligent Technology, has been recommended as a candidate for a procurement project that includes key electrical equipment such as overhead insulated wires and 10KV transformers [1][2]. - Since 2025, Samsung Medical has secured significant orders, with a total order backlog of 17.914 billion yuan as of the end of the third quarter of 2025, representing a year-on-year increase of 14.69% [1][2]. Group 2: Financial Performance - The company reported revenues of 9.098 billion yuan, 11.46 billion yuan, and 14.6 billion yuan for the years 2022 to 2024, with year-on-year growth rates of 29.55%, 25.99%, and 27.38% respectively [4][5]. - In the first three quarters of 2025, the company achieved revenue of 11.08 billion yuan, a year-on-year increase of 6.19%, but the net profit attributable to shareholders decreased by 15.85% to 1.528 billion yuan [5]. Group 3: Research and Development - Samsung Medical has invested heavily in R&D, with total R&D expenses exceeding 2.037 billion yuan over the past five years, which has strengthened its technological capabilities and product competitiveness [4][6]. - The company has received 32 automation patents in the last three years and is advancing its "smart manufacturing" strategy, including the establishment of the industry's first digital factory [6].